ÂÜÀòÂÒÂ×

Matthew Ros has extensive experience in the biotech and pharmaceutical industries, currently serving as a Board Member at Cogent Biosciences since July 2019, where Matthew is part of the Audit and Nomination and Governance Committees. Previously, as Chief Executive Officer and Board Member at Fore Biotherapeutics from April 2022 to September 2023, Matthew led the development of a BRAF inhibitor for treating CNS malignancies and achieved significant regulatory milestones. At Epizyme from May 2016 to October 2021, Matthew held the position of Executive Vice President, Chief Strategy and Business Officer, overseeing corporate strategy and various operational functions. Earlier roles include Vice President and COO at Sanofi Genzyme, Senior Vice President of Commercial Operations at ARIAD Pharmaceuticals, and Senior Director of Oncology Marketing at Bristol-Myers Squibb, where Matthew gained expertise in oncology marketing and commercialization. Matthew holds a BS in Business Administration from the State University of New York at Plattsburgh.